Quantcast
 
New ETF Book by Larry Connors - Click here to read more


 

ValiMed Pay-Per-Use Pricing Program Positively Received by Hospitals to Enhance Patient Safety and Reduce Narcotic Diversion

Thu. July 30, 2009; Posted: 09:03 AM
Stocks RSS
TUCSON, AZ, Jul 30, 2009 (MARKETWIRE via COMTEX) -- CEXI | Quote | Chart | News | PowerRating -- CDEX Inc. (OTCBB: CEXI | Quote | Chart | News | PowerRating) (www.cdexinc.com), the developers and marketers of the ValiMed(TM) Medication Validation System for the in-patient hospital pharmacy, implemented a new and innovative pricing plan which allows hospitals to afford this life saving medication safety technology on a "Pay-Per-Use" basis.

"By also offering a Pay-Per-Use Pricing as an alternative to capital purchase, CDEX positions its ValiMed technology to be in reach of every hospital no matter size or specialty," said Greg Firmbach, Senior Vice President of CDEX. "Pay-Per-Use pricing is an all inclusive turnkey approach to placing life-saving technology with equipment, supplies and service all for around $2.50 per test. The reaction in the marketplace has been very positive as hospitals are now reviewing the integration of multiple ValiMed units into their medication safety programs for only the cost of supplies, an operating budget item."

ValiMed is used to validate "The Right Drug at The Right Dose" when high-risk liquid medications are compounded in a pharmacy setting and also as a verification program to reduce the diversion of return narcotics in hospitals and other healthcare facilities. CDEX expects demand to continue to build as the health system pharmacists, patient safety agencies and associations and the Joint Commission become more aware of the availability of ValiMed at these prices.

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed(TM) product line provides life-saving validation of high-risk medications and returned narcotics. The ID2(TM) product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements

Contact:
Malcolm Philips
Email Contact


SOURCE: CDEX Inc.

http://www2.marketwire.com/mw/emailprcntct?id=6B2ABF53F298B645
For full details for CEXI click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [CEXI]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.